公开(公告)号：US11628138B2

公开(公告)日：2023-04-18

申请号：US17730305

申请日：2022-04-27

申请人： FARMAKEIO OUTSOURCING, LLC

发明人： Cody Boatman ,  Daniel DeNeui ,  Justin Graves

IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K31/568 ,  A61K31/573

摘要： Disclosed herein are compositions useful for treating hypogonadism in men and women. The disclosed compositions comprise an admixture of testosterone and triamcinolone which combination alleviates pellet injection site pain and/or discomfort, as well as pellet extrusion.

公开(公告)号：US20230115710A1

公开(公告)日：2023-04-13

申请号：US18064767

申请日：2022-12-12

申请人： THEAPRIN PHARMACEUTICALS, INC.

发明人： Philip V. FELICE ,  Harry G. BRITTAIN

IPC分类号： A61K9/00 ,  A61K9/14 ,  A61K9/20 ,  A61K31/616

摘要： A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.

公开(公告)号：US11622952B2

公开(公告)日：2023-04-11

申请号：US16638533

申请日：2018-08-15

申请人： Evonik Operations GmbH

发明人： Thomas Gottstein ,  Michael Schwarm ,  Guenter Knaup

IPC分类号： A61K31/202 ,  A23L33/12 ,  A23L33/175 ,  A61K9/20 ,  A61K31/198

摘要： The present invention relates to a tablet comprising one or more omega-3 fatty acid amino acid salts, a method for preparing a tablet according to the invention and the use of a tablet according to the invention as a food supplement or as a pharmaceutical product.

公开(公告)号：US11622939B2

公开(公告)日：2023-04-11

申请号：US16766292

申请日：2018-11-23

申请人： ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.

发明人： Li Ding ,  Jun Dai ,  Chunrong Feng ,  Changliang Dai

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K31/397

摘要： An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.

公开(公告)号：US11622938B2

公开(公告)日：2023-04-11

申请号：US16094654

申请日：2017-04-18

申请人： CONARIS RESEARCH INSTITUTE AG

发明人： Alfred Chi Yeh Liang ,  Venkataramana Dingari

IPC分类号： A61K9/20 ,  A61K31/455 ,  A61K31/606

摘要： Described herein are pharmaceutical compositions for the oral administration of nicotinamide, or a combination of nicotinamide and mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of nicotinamide or a combination of nicotinamide and mesalazine.

公开(公告)号：US20230101484A1

公开(公告)日：2023-03-30

申请号：US17784200

申请日：2020-12-11

申请人： NIPPON SHINYAKU CO., LTD.

发明人： Junshi ASADA ,  Yoshinari HARUTA ,  Hiroyuki YAKUSHIJI ,  Toru TANAKA ,  Kazuya KURAMOTO ,  Keiji KOSUGI ,  Chiaki FUCHIKAMI

IPC分类号： C07D213/82 ,  A61K9/20 ,  C07D277/56 ,  C07D263/34 ,  C07D513/04 ,  C07D401/12 ,  C07D213/56 ,  C07D241/12 ,  C07D241/20 ,  C07D401/04 ,  C07D239/84 ,  C07D471/04 ,  C07D215/12 ,  C07D405/04 ,  C07D495/04 ,  C07D487/04 ,  C07D413/04 ,  C07D413/12 ,  A61P11/00 ,  C07D213/81

摘要： An object of the present invention is to provide a compound having a PDGF receptor kinase inhibitory activity.
Examples of the present invention may include, for example, a compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof. The compound of the present invention has an inhibitory activity against the PDGF receptor kinase. In addition, since the compound of the present invention has an inhibitory activity against the PDGF receptor kinase, it is useful as a therapeutic agent for respiratory diseases, cancers, smooth muscle proliferative diseases, vasoproliferative diseases, autoimmune/inflammatory diseases, metabolic diseases, vasoocclusive diseases, and the like.

公开(公告)号：US20230096218A1

公开(公告)日：2023-03-30

申请号：US17769666

申请日：2020-10-16

申请人： BALTICGRUPPEN BIO AB

发明人： Thomas EDLUND ,  Jacob WESTMAN

IPC分类号： C07D285/08 ,  A61K9/48 ,  A61K9/20 ,  A61K9/28 ,  A61K9/14

摘要： There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1, 2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

公开(公告)号：US11612568B2

公开(公告)日：2023-03-28

申请号：US16852342

申请日：2020-04-17

申请人： DFE Pharma GmbH & Co. KG

发明人： Korinde Van Den Heuvel ,  Bas Van Laarhoven ,  Eva Maria Janssen ,  Mara Maria Wilhelmina Van Haandel

IPC分类号： A61K9/20 ,  A61K31/167

摘要： The invention relates to a method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg—comprising an active ingredient selected from the group of pharmaceutical substances and active substances for a dietary supplement or nutraceutical, comprising (a) providing a lactose agglomerate comprising lactose, and a sugar alcohol; (b) providing the active ingredient; (c) mixing the agglomerate and the active ingredient, thereby obtaining a mixture; and (d) forming the tablet by direct compression.

公开(公告)号：US20230092397A1

公开(公告)日：2023-03-23

申请号：US17821905

申请日：2022-08-24

申请人： SANIONA A/S

发明人： Peter G. NIELSEN ,  Mikael S. THOMSEN ,  Bent HØJGAARD

IPC分类号： A61K31/403 ,  A61K45/06 ,  A61K31/138 ,  A61K31/46 ,  A61K9/20 ,  A61K9/24 ,  A61K9/28

摘要： The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

公开(公告)号：US20230092353A1

公开(公告)日：2023-03-23

申请号：US17968232

申请日：2022-10-18

申请人： Arena Pharmaceuticals, Inc.

发明人： Cheryl Geraldine Lassen

IPC分类号： A61K31/404 ,  A61P17/02 ,  A61P1/04 ,  A61K9/20 ,  A61K45/06

摘要： The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(triflu-oromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of extra-intestinal manifestations (EIM) in an individual with inflammatory bowel disease (BBD) and for the treatment of pyoderma gangrenosum (PG). In some embodiments, the methods further comprise administering Compound 1, or a harmaceutically salt, solvate, or hydrate thereof, in combination with a therapeutically effective amount of a compound selected from the group consisting of: a corticosteroid, a 5-aminosalicylic acid derivative, and a TNF-alpha inhibitor; or a corticosteroid, an immunosuppressant, a biologic, an anti-inflammatory agent, and an antibiotic.